AG
WST icon

AIA Group’s West Pharmaceutical WST Stock Holding History

AIA Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,172
Closed -$413K – 348
2023
Q4 		$413K Sell
1,172
-214
-15% -$75.7K 0.02% 243
2023
Q3 		$520K Sell
1,386
-2,182
-61% -$844K 0.03% 214
2023
Q2 		$1.36M Buy
3,568
+3,207
+888% +$1.15M 0.07% 139
2023
Q1 		$125K Hold
361
– – 0.01% 357
2022
Q4 		$85K Sell
361
-468
-56% -$111K 0.01% 373
2022
Q3 		$204K Sell
829
-511
-38% -$156K 0.01% 292
2022
Q2 		$405K Sell
1,340
-65
-5% -$21.1K 0.02% 264
2022
Q1 		$577K Buy
1,405
+403
+40% +$158K 0.03% 216
2021
Q4 		$470K Buy
1,002
+238
+31% +$102K 0.02% 188
2021
Q3 		$324K Buy
764
+127
+20% +$53.5K 0.02% 212
2021
Q2 		$236K Buy
+637
New +$210K 0.02% 201

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AIA Group's WST Position: Q1 2024 in Review

AIA Group sold out of West Pharmaceutical (WST) in Q1 2024, closing a stake of 1,172 shares — an estimated $413K sold.

AIA Group first reported a position in WST in Q2 2021 and held it in 11 quarters. The position peaked at $1.36M in Q2 2023. 778 funds tracked by Wall St. Rank hold WST as of Q1 2024.

  • AIA Group reported no remaining West Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • AIA Group sold 1,172 West Pharmaceutical shares in Q1 2024, an estimated $413K.
  • AIA Group first reported a position in West Pharmaceutical in Q2 2021 and held it in 11 quarters.
  • AIA Group's West Pharmaceutical position peaked at $1.36M in Q2 2023.
  • 778 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2024.

Based on AIA Group's 13F filing for Q1 2024, filed 6 May 2024.